Clinical TrialJul 27, 2026, 07:02 AM
CAMP4 Therapeutics Gets TGA Clearance for SYNGAP1 Trial; Secures $50M Funding
AI Summary
CAMP4 Therapeutics announced it received clearance from Australia’s TGA and HREC to initiate a Phase 1/2 clinical trial for CMP-002, a potential disease-modifying therapeutic for SYNGAP1-related disorder. This regulatory milestone enables the company to proceed with the second closing of a private placement, allowing it to raise up to an additional $50 million. The funding will support the advancement of CMP-002 and its broader pipeline, with the closing expected within five business days.
Key Highlights
- Received TGA and HREC clearance for Phase 1/2 clinical trial of CMP-002.
- CMP-002 is a potential first-in-class therapeutic for SYNGAP1-related disorder.
- Clearance satisfies a regulatory milestone for a September 2025 private placement.
- Eligible to receive up to an additional $50 million in gross proceeds.
- Second closing of the private placement is expected within five business days.
- Investors include Coastlands Capital, Janus Henderson, and Balyasny Asset Management.
- Australia selected as an initial enrollment site for the Phase 1/2 trial.
Price Impact
More from CAMP